News of Note—Mylan now recalling 104 lots of valsartan medications


> Mylan, after initially recalling just 15 lots of valsartan-based drugs that it says were tainted by a carcinogen, has now expanded its consumer-level voluntary nationwide recall to include all 104 lots of valsartan-containing products within expiry. Release

> Boehringer Ingelheim has sold its synthetic API plant to Japan’s AGC which will now have its first FDA-approved facility in Europe in the CDMO business. Release

> After putting South Korea’s Barox on its import alert list, the FDA has issued a warning letter to the OTC repackager. Warning letter


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

> The FDA has issued a Form 483 to Gadea Biopharma in Leon, Spain, after an inspection of the sterile drug manufacturer lacked some of the basic processes for producing drugs. Form 483

Suggested Articles

Sanofi, which has moved purposefully into high technologies to get more from its manufacturing, will lean even more on that strategy to save costs.

Just months after a C-suite shakeup at Amneal, the generics company has struck a $220 million deal for AvKare, known on the street as R&S Northeast. 

Fujifilm has completed the first manufacturing facility in Japan to make drug-delivering liposomes to use for cancer fighting drugs it is developing.